[Endocrine adjuvant treatment specific features for young breast cancer women]

Abstract

For young patients with hormone receptor-positive early breast cancer, tamoxifen for at least 5 years is the standard endocrine treatment. Prolonged endocrine treatment over 5 years is recommended for patients with high risk of late relapse. When adjuvant chemotherapy is indicated, prolonged iatrogenic amenorrhea is a strong pronostic factor. WIthout persistant amenorrhea after chemotherapy, it is indicated to associate ovarian suppression to the endocrine treatment. Optimal duration of this induced amenorrhea is unknown.

Keywords: Adjuvant setting; Amenorrhea; Aménorrhée; Breast cancer; Cancer du sein; Endocrine treatment; Femme jeune; Hormonothérapie; Traitement adjuvant; Young woman.